Health officials debate easing restrictions on experimental peptide BPC-157 amid safety concerns
A federal panel voted to allow certain unapproved peptides to be compounded for human use, prompting criticism from scientists and reports of adverse effects from users.
A panel advising the Food and Drug Administration voted in July to add six experimental peptides, including BPC-157, TB-500 and MOTS-c, to the 503A bulk-list that would let specialized pharmacies compound them for human consumption. The move is part of a broader effort by the Department of Health and Human Services, led by Health Secretary Robert F. Kennedy Jr., to reduce regulatory barriers for peptides promoted as health-optimizing substances.
The vote ran counter to FDA scientists who presented data indicating insufficient evidence of benefit and highlighted potential risks such as liver toxicity, allergic reactions and other serious outcomes.
"If you want to take an experimental drug, you ought to be able to do that," Kennedy said on a podcast, emphasizing patient choice over regulatory restriction.
Critics argue the decision could discourage investment in rigorous clinical trials. Eric Topol, executive vice president of Scripps Research, warned that the lack of approved studies may leave consumers vulnerable to “predators that will sell, sell, sell.”
Personal accounts illustrate the concerns. Dylan Meetze, who used BPC-157 after hearing it recommended by a popular neuroscience podcaster, reported prolonged fatigue, anxiety, muscle twitches and visual disturbances. Another user described severe migraines and facial numbness after combining BPC-157 with TB-4. Reports of hospitalizations linked to experimental peptide use have also appeared in FDA adverse-event databases.
Proponents, including members of the Make America Healthy Again movement, cite anecdotal success stories and argue that compounding pharmacies can ensure product safety. However, former FDA official Peter Lurie cautioned that compounding facilities are often subject to lax oversight and that adding unapproved peptides to the bulk-list could mislead consumers into believing the substances have proven clinical benefit.
The FDA has not yet issued a final ruling, and the debate continues over whether expanding access to these peptides serves public health or undermines the evidentiary standards required for drug approval.